From CFTR to a CF Signalling Network: a Systems Biology Approach to Study Cystic Fibrosis

Overview

Journal BMC Genomics

Publisher Biomed Central

Specialty Genetics

Date 2024 Sep 28

PMID 39342081

Authors

Matthieu Najm

Loredana Martignetti

Matthieu Cornet

Mairead Kelly-Aubert

Isabelle Sermet

Laurence Calzone

Veronique Stoven

Affiliations

Soon will be listed here.

Abstract

Background: Cystic Fibrosis (CF) is a monogenic disease caused by mutations in the gene coding the Cystic Fibrosis Transmembrane Regulator (CFTR) protein, but its overall physio-pathology cannot be solely explained by the loss of the CFTR chloride channel function. Indeed, CFTR belongs to a yet not fully deciphered network of proteins participating in various signalling pathways.

Methods: We propose a systems biology approach to study how the absence of the CFTR protein at the membrane leads to perturbation of these pathways, resulting in a panel of deleterious CF cellular phenotypes.

Results: Based on publicly available transcriptomic datasets, we built and analyzed a CF network that recapitulates signalling dysregulations. The CF network topology and its resulting phenotypes were found to be consistent with CF pathology.

Conclusion: Analysis of the network topology highlighted a few proteins that may initiate the propagation of dysregulations, those that trigger CF cellular phenotypes, and suggested several candidate therapeutic targets. Although our research is focused on CF, the global approach proposed in the present paper could also be followed to study other rare monogenic diseases.

References

Szalai B, Saez-Rodriguez J . Why do pathway methods work better than they should?. FEBS Lett. 2020; 594(24):4189-4200. DOI: 10.1002/1873-3468.14011. View

Conese M, Di Gioia S . Pathophysiology of Lung Disease and Wound Repair in Cystic Fibrosis. Pathophysiology. 2022; 28(1):155-188. PMC: 8830450. DOI: 10.3390/pathophysiology28010011. View

Buccitelli C, Selbach M . mRNAs, proteins and the emerging principles of gene expression control. Nat Rev Genet. 2020; 21(10):630-644. DOI: 10.1038/s41576-020-0258-4. View

Hornberg J, Bruggeman F, Westerhoff H, Lankelma J . Cancer: a Systems Biology disease. Biosystems. 2006; 83(2-3):81-90. DOI: 10.1016/j.biosystems.2005.05.014. View

Dugger D, Fung M, Zlock L, Caldera S, Sharp L, Hays S . Cystic Fibrosis Lung Transplant Recipients Have Suppressed Airway Interferon Responses during Infection. Cell Rep Med. 2020; 1(4). PMC: 7402593. DOI: 10.1016/j.xcrm.2020.100055. View

Lasalvia M, Castellani S, DAntonio P, Perna G, Carbone A, Colia A . Human airway epithelial cells investigated by atomic force microscopy: A hint to cystic fibrosis epithelial pathology. Exp Cell Res. 2016; 348(1):46-55. DOI: 10.1016/j.yexcr.2016.08.025. View

Dorfman R, Sandford A, Taylor C, Huang B, Frangolias D, Wang Y . Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest. 2008; 118(3):1040-9. PMC: 2248329. DOI: 10.1172/JCI33754. View

Durinck S, Spellman P, Birney E, Huber W . Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc. 2009; 4(8):1184-91. PMC: 3159387. DOI: 10.1038/nprot.2009.97. View

Keating D, Marigowda G, Burr L, Daines C, Mall M, McKone E . VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018; 379(17):1612-1620. PMC: 6289290. DOI: 10.1056/NEJMoa1807120. View

10.

Ghigo A, Prono G, Riccardi E, De Rose V . Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches. Int J Mol Sci. 2021; 22(4). PMC: 7920244. DOI: 10.3390/ijms22041952. View

11.

Kramer E, Clancy J . TGFβ as a therapeutic target in cystic fibrosis. Expert Opin Ther Targets. 2017; 22(2):177-189. PMC: 6094931. DOI: 10.1080/14728222.2018.1406922. View

12.

Massip Copiz M, Santa Coloma T . c- Src and its role in cystic fibrosis. Eur J Cell Biol. 2016; 95(10):401-413. DOI: 10.1016/j.ejcb.2016.08.001. View

13.

Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S . The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016; 54:1.30.1-1.30.33. DOI: 10.1002/cpbi.5. View

14.

Pankonien I, Quaresma M, Rodrigues C, Amaral M . CFTR, Cell Junctions and the Cytoskeleton. Int J Mol Sci. 2022; 23(5). PMC: 8910340. DOI: 10.3390/ijms23052688. View

15.

Fleurot I, Lopez-Galvez R, Barbry P, Guillon A, Si-Tahar M, Bahr A . TLR5 signalling is hyper-responsive in porcine cystic fibrosis airways epithelium. J Cyst Fibros. 2021; 21(2):e117-e121. DOI: 10.1016/j.jcf.2021.08.002. View

16.

Sagwal S, Chauhan A, Kaur J, Prasad R, Singh M, Singh M . Association of Serum TGF-β1 Levels with Different Clinical Phenotypes of Cystic Fibrosis Exacerbation. Lung. 2020; 198(2):377-383. DOI: 10.1007/s00408-020-00320-x. View

17.

Natarajan V . Is PI3K a Villain in Cystic Fibrosis?. Am J Respir Cell Mol Biol. 2020; 62(5):552-553. PMC: 7193793. DOI: 10.1165/rcmb.2020-0029ED. View

18.

Thurman A, Li X, Villacreses R, Yu W, Gong H, Mather S . A Single-Cell Atlas of Large and Small Airways at Birth in a Porcine Model of Cystic Fibrosis. Am J Respir Cell Mol Biol. 2022; 66(6):612-622. PMC: 9163647. DOI: 10.1165/rcmb.2021-0499OC. View

19.

De Lisle R . Disrupted tight junctions in the small intestine of cystic fibrosis mice. Cell Tissue Res. 2013; 355(1):131-42. PMC: 3904805. DOI: 10.1007/s00441-013-1734-3. View

20.

Kosamo S, Hisert K, Dmyterko V, Nguyen C, Black R, Holden T . Strong toll-like receptor responses in cystic fibrosis patients are associated with higher lung function. J Cyst Fibros. 2019; 19(4):608-613. PMC: 7272272. DOI: 10.1016/j.jcf.2019.11.009. View